CERO · Cero Therapeutics Holdings, Inc.
$0.01
+0.00 (+0.00%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$451,124
Shares
45.11M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brian G. Atwood | CEO | $1,806,508 |
| Daniel Corey | CEO | $1,073,213 |
| Chris Ehrlich | CEO | $998,748 |
| Charles R. Carter | CFO | $690,262 |
| Kristen Pierce | Chief Development Officer | $119,777 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel Corey | CEO | $376,035 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel Corey | CEO | $372,685 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eric Francois | director | Appointed | 2026-02-13 |
| Andrew Albert Kucharchuk | Chief Financial Officer | Appointed | 2025-06-02 |
| Chris Ehrlich | Chief Executive Officer | Appointed | 2025-06-02 |
| Lindsey Rolfe, M.D. | Class I director | Appointed | 2025-05-29 |
| Michael Byrnes | Class I director | Appointed | 2025-05-29 |